# Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab

> **NCT03149159** · PHASE2 · WITHDRAWN · sponsor: **Medical University of South Carolina**

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **RADIATION:** Steriotactic radiation therapy

## Key facts

- **NCT ID:** NCT03149159
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-04-01
- **Primary completion:** 2018-04-01
- **Final completion:** 2018-04-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study is withdrawn due to feasibility issues.
- **Last updated:** 2018-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03149159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03149159, "Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03149159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*